aTyr Pharma to Present at Life Sciences Investor Forum on September 17th
September 02 2020 - 7:00AM
aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics
company engaged in the discovery and development of innovative
medicines based on novel immunological pathways, today announced
that Sanjay S. Shukla, M.D., M.S., President and Chief Executive
Officer, will present a company overview at the Virtual Life
Sciences Investor Forum, which is being held on Thursday, September
17.
Details of the event are as follows:
Date: Thursday September 17, 2020 Presentation
Time: 11:30 a.m. Eastern TimeWebcast Link: https://bit.ly/30GjErk
This will be a live, interactive online event where investors are
invited to ask the Company questions in real-time. The presentation
and Q&A session will be webcast live and can be accessed at
www.lifesciencesinvestorforum.com. Investors are encouraged to
pre-register to expedite participation and receive event updates.
Please access the website at least 15 minutes in advance of the
scheduled presentation time to register and run the online system
check.
Please visit www.lifesciencesinvestorforum.com
to register and learn more about the event.
Recent Company Highlights:
- Progression of Ongoing Phase 1b/2a Trial of ATYR1923 in
Patients with Pulmonary Sarcoidosis
- Initiation of a Phase 2 Trial of ATYR1923 in COVID-19 Patients
with Severe Respiratory Complications
- Publication of Two Abstracts in the American Journal of
Respiratory and Critical Care Medicine and Presentation of Posters
at the American Thoracic Society Annual Meeting Demonstrating that
ATYR1923 Selectively Binds to NRP2 and NRP2 is Expressed in Sarcoid
Granulomas
- Presentation of Preclinical Research Showing NRP2 Antibody
Effects in Triple-Negative Breast Cancer at the American
Association for Cancer Research Virtual Annual Meeting II
- Initiation of Phase 1 Trial of ATYR1923 in Japanese Healthy
Volunteers by Partner Kyorin Pharmaceutical
A replay of the presentation will be available
following the event on the Investor’s section of the Company’s
website at www.atyrpharma.com. About
aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
immunological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
About
Life Sciences Investor Forum
Life Sciences Investor Forum is the leading proprietary investor
conference series that provides an interactive forum for Life
Sciences companies to meet with and present directly to investors.
A real-time solution for investor engagement, Life Sciences
Investor Forum is powered by Intrado Digital Media and specifically
designed for more efficient investor access. Replicating the look
and feel of on-site investor conferences, Life Sciences Investor
Forum combines leading-edge conferencing and investor
communications capabilities with a comprehensive global investor
audience network.
Contact:
Ashlee Dunston
Investor Relations, aTyr Pharma
adunston@atyrpharma.com
Life Sciences Investor Forum
John M. Viglotti
SVP Corporate Services, Investor Access
(212) 220-2221
johnv@lifesciencesinvestorforum.com
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Sep 2023 to Sep 2024